



Open  Access

Review Article

Floating type drug delivery system: A review

S. K. Datir*¹, P.B. Patil¹, R.B. Saudagar²

¹ Department of Pharmaceutics, KCT'S RGS College of Pharmacy, Anjaneri, Nasik, 422 213. Maharashtra, India.

² Department of Pharmaceutical Chemistry, KCT'S RGS College of Pharmacy, Anjaneri, Nasik, 422 213. Maharashtra, India

ABSTRACT

Floating Type drug delivery system retains the dosage form for a long span. They provide local delivery to specific region like stomach and proximal small intestine and shows better bioavailability and improve therapeutic activity and substantial benefit to patients. FDSS is one of the novel drug delivery system to prolong gastric retention time. Various forms of gastro retentive drug delivery system, such as floating and non-floating.

Keywords: Floating Drug Delivery System, Classification effervescent, non-effervescent, and Factors affecting FDSS.

Article Info: Received 24 Jan 2019; Review Completed 27 Feb 2019; Accepted 03 March 2019; Available online 15 March 2019



Cite this article as:

Datir SK, Patil PB, Saudagar RB, Floating type drug delivery system: A review: Journal of Drug Delivery and Therapeutics. 2019; 9(2):428-432 <http://dx.doi.org/10.22270/jddt.v9i2.2492>

*Address for Correspondence:

S. K. Datir, Department of Pharmaceutics, KCT'S RGS College of Pharmacy, Anjaneri, Nasik, 422 213. Maharashtra, India.

INTRODUCTION

The high level of patient compliance in taking oral dosage form is due to the ease of administration, patient compliance, flexibility in formulation and handling of this form. Although tremendous advances have been seen in oral controlled drug delivery system during last two decades. This system has been of limited success. This approach is bailed with several physiological difficulties such as inability to restrain and locate the controlled drug delivery system within the desired region of the gastrointestinal tract (GIT) due to variable gastric emptying and mobility. Normal gastric residence times usually range between 5 minutes and 2 hours. Migrating myoelectric complex is characterized by four phases: Phase 1-Period of no contraction (40-60 minutes), phase 2-Period of intermittent contraction (20-40 minutes), Phase 3-period of regular contraction at the maximal frequency 20 minutes and phase 4-Period of transition between phase 3 And Phase 1 (0.5minutes)¹ (figure 1)¹

Gastro retentive system can remain in the gastric region for several hours and hence significantly prolong the gastric residence time of drugs. Prolonged gastric retention improves bioavailability, reduces drug waste, and improves solubility for drugs that are less soluble in a high pH environment. It has applications also for local drug delivery to the stomach and proximal. Slowed mobility of the gastrointestinal tract by concomitant administration of drugs or pharmaceutical excipient also increases gastric retention

of drug. These efforts resulted in GRDSs that were designed, in large part, based on the following approaches. (Figure: 2)³

Low density form of the DF that causes buoyancy in gastric fluid.

High density DF that is retained in the bottom of the stomach.

Bio adhesion to the stomach mucosa.

Expansion by swelling or unfolding to a large size which limits passage of dosage form through the pyloric sphincter.³




Figure 1: Schematic Representation of Interdigestive Motility




Figure 2:Types of Gastro - retentive drug delivery system

CLASSIFICATION OF FLOATING TYPE DRUG DELIVERY SYSTEM

A.Single Unit Floating Dosage System

- a. Effervescent System (Gas Generating System)
- b. Non-effervescent Systems

B.Multiple Unit Floating Dosage Systems

- a. Non- effervescent systems
- b. Effervescent System (Gas- Generating System)
- c. Hollow Microsphere
- d. Raft Forming Systems⁴

A. Single Unit Dosage Form

a. Effervescent System (Gas-Generating System)

effervescent system are matrix type of systems this are prepared with the help of swell able polymers such as methylcellulose and chitosan and various effervescent components like sodium bicarbonate, citric acid and tartaric acid or chamber containing a liquid that gaffes at body temperature.(Fig:3)¹ The optimal stoichiometric ratio of citric acid and sodium bicarbonate for gas generation is reported to be 0.76:1. The common approach for preparing these system involves resin beads loaded with bicarbonate and coated with ethylcellulose.Excipient used most commonly in these system include HPMC, polyacrylate polymers, polyvinyl acetate, carbopol ,agar sodium alginate, calcium chloride, polyethylene oxide and polycarbonates⁴ .




Figure: 3 Gas-Generating System

b. Non-effervescent System

One or more gel forming, highly swell able, cellulosic hydrocolloids (e.g. hydroxyl ethyl cellulose, hydroxyl propy

l cellulose and sodium carboxyl methyl cellulose), polysaccharides, or matrix forming polymers(e.g., polycarbophil, polyacrylate, and polystyrene) are incorporated in high level (20 75% w/w) to tablets or capsules. For the preparation of these types of systems, the drug and t he gel-forming hydrocolloid are mixed thoroughly. After oral administration this dosage form swells in contact with gastri c fluids and attains a bulk density of <1.⁵

B. Multiple Unit Floating Dosage Form

a. Non-effervescent system

Alginate Beads

They were made using a combination and low methoxylated pectin. Spherical beads of approximately 2.5 mm in diameter can be prepared by dropping a sodium alginate solution in to aqueous solutions of calcium chloride, causing precipitation of calcium alginate. The beads are then separated snap and frozen in liquid nitrogen, and freeze dried at -40° for 24 h, leading to the formation of porous system, which can maintain a floating force over 12 h. Yong-Dan Tang et. Al prepared alginate beads based on the above method for the sustained release of both hydrophobic and hydrophilic drugs. They added sunflower oil in the beads and found the beads floating for 24 hours. The hydrophobic drug ibuprofen was released from this system for 24 hours due to oil partitioning.⁶

b. Effervescent System

Floating pills

These systems consist of sustained release pills as ‘seeds’ surrounded by double layers. The inner layer consists of effervescent agents like sodium carbonate while the outer layer is of swell able polymer like polyvinyl acetate. When this system is immersed in to dissolution medium at body temp, it sinks at once and then forms swollen pills like balloons which then float as they have lower density. This lower density is due to generation and entrapment of CO2 within the system⁷ (Fig. 4)⁷




Figure 4:

(A) Multiple-unit oral floating drug delivery system.

(B) Working principle of effervescent floating drug delivery system.

c. Microballoons / Hollow microspheres

These are loaded with drugs in their other polymer shell were prepared by simple solvent evaporation. (Figure 5)¹ to prolong the gastric retention time (GRT) of the dosage form. Polycarbonate, Eudragit S, Cellulose acetate, calcium alginate agar and low methoxylated pectin are commonly used polymers in preparation of hollow microsphere. Buoyancy and drug release are dependent on quantity of etc. Buoyancy and drug release from dosage form are dependent on quantity of polymers, the plasticizer polymer ratio and the solvent used for formulation. The micro balloons floated continuously over the surface of an acidic dissolution media containing surfactant for >12 hours.⁸ Buoyancy and drug release are dependent on quantity of polymer, the plasticizer-polymer ratio and the solvent used.^{1,8}




Figure: 5 Micro balloons

D. Raft Forming System

On contact with gastric fluid a gel-forming solution (sodium alginate solution containing carbonate or bicarbonate) swells and forms a viscous cohesive gel containing entrapped CO₂ bubbles.¹ Which forms a raft layer on top of gastric fluid which releases drugs slowly in stomach. Such formation typically contains antacids such as aluminium hydroxide or calcium carbonate to reduce gastric acidity. They are often used for gastro esophageal reflux treatment as with liquid gaviscon⁹ (GlascoSmithline) (FIG.6)¹⁰




Figure: 6 Barrier formed by a raft-forming system

MECHANISM OF FDDS

There are various attempts that have been made to retain the dosage form in the stomach as a way of increasing the retention time. These attempts include introducing the floating dosage form as a gas generating system and swelling

system modified shape system. Gastric emptying delaying devices and co-administration of gastric-emptying delaying drugs. Among these, the floating dosage form has been most commonly used. Floating drug delivery systems have a bulk density less than gastric fluid and so remain buoyant in the stomach without affecting the gastric emptying rate for a prolonged period of time. While the system is floating on the gastric content, (fig.7a)¹¹ the drug is released slowly at the desired rate from the system. This results in an increased GRT, better control of the fluctuation in plasma drug concentration. After the release of drug, the residual system is emptied from the stomach. However, beside a minimal gastric content needed to allow the proper achievement of the buoyancy retention principle, a minimal level of floating force (F) is also required to keep the dosage form reliably buoyant on the surface of the meal. To measure the floating force kinetic, a novel apparatus for determination of resultant weight has been reported in the literature. The apparatus operates by measuring continuously the force equivalent to F is on the higher positive side (fig.7b)¹¹. apparatus help in optimizing FDDS with respect to stability and durability of floating forces produced in order to prevent the drawback of unforeseeable intragastric buoyancy capability variations.¹¹




Figure: 7 Different mechanisms of floating systems.

$$F = F_{\text{buoyancy}} - F_{\text{gravity}} = (D_f - D_s)gv$$

Where, F = total vertical force
 D_f = fluid density
 D_s = Object density
 V = volume and
 G = acceleration due to gravity

FACTORS AFFECTING FDDS

Density: Floating is a function of dosage form buoyancy that is dependent on the density.

Shape of the dosage form: ring shaped and Tetrahedron device with flexural modulus of 48 and 22.5 kilo pounds per square inch (KSI) are reported to have better floating, 90% to 100% retention at 24 hours as compared with other shapes.¹²

Concomitant drug administration: Anticholinergic like atropine and propantheline, prokinetic agents like metoclopramide and cisapride; can affect floating time

Fed or Unfed State: Under fasting conditions, the GI mobility is characterized by periods of strong motor activity or the migrating myoelectric complex (MMC) that occurs every 1.5 to 2 hours.

Nature of meal: Feeding of indigestible polymers or fatty acid salts can change the motility pattern of the stomach to a fed state, thus decreasing the gastric emptying rate and prolonging drug release.

Caloric content and feeding frequency: Floating can be increased by four to 10 hours with a meal that is high in protein and fats. The floating can increase by over 400 minutes when successive meals are given compared with a single meal due to low frequency of MMC.

Age: Elderly people, especially those over 70, have a significantly longer floating time. Disease conditions such as diabetes and Crohn's disease etc also affect drug delivery.

Posture: Floating can vary between supine and upright ambulatory states of the patients.¹³

ADVANTAGES OF FDDS

Sustained drug delivery: A floating drug delivery system can remain in the stomach for several hours and the assumed prolongation in the gastric retention is postulated to cause sustained drug release behaviour.

Site-specific drug delivery: Targeting of drug¹⁴ to stomach appears to be useful for all substances intended to produce a lasting local action on the gastro duodenal wall.

Pharmacokinetic advantage: In addition, with the total gastrointestinal transit duration is increased, a greater amount of drug may be delivered and thus the relative bioavailability will consequently be increased.

Reduced counter-activity of the body: Slow input of the drug into the body was shown to minimize the counter activity leading to higher drug efficiency.¹¹

Improves patient compliance.

Freedom from incompatibilities between drug and excipients especially with buffers.

Better therapeutic effect of short half life drugs can be achieved.

Gastric retention time is increased because of buoyancy.

Site specific drug delivery to the stomach can be achieved.^{15,16}

DISADVANTAGES OF FDDS

These systems require a high level of fluid in the stomach for drug delivery to float and work efficiently-coat, water.

The drugs that are significantly absorbed throughout the gastrointestinal tract, which undergo significant first pass metabolism, are only desirable candidates.

Gastric Irritation due to the presence of some drug in the Floating Type Drug Delivery System.

These systems require a high level of fluid in the stomach for drug delivery to float however this can be overcome by using low density polymers.¹¹

The release rate of the controlled release dosage form varies from a variety of factors like rate of food transit through the drug. 3) Potential toxicity due to loss of integrity of drugs.

The dosage forms should be administered with more amount of water (200-250ml).

These dosage forms should not be crushed or chewed.¹⁵

PROBABLE CANDIDATES FOR FDDS

Following are the probable candidates, but not limited to, for gastro retentive drug delivery system:

Drugs required exerting local therapeutic action in the stomach: antacids, anti-H.pylori agents, misoprostol

Drugs that have narrow absorption window in stomach or upper parts of the small intestine, e.g., furosemide, riboflavine-5-phosphate¹⁷

EVALUATION PARAMETER OF FDDS

A. In Vitro Methods

1. Floating Lag Time And Floating Time

It is the time taken by the tablet to emerge on to the surface of dissolution medium and is expressed in seconds or minutes.¹⁸ In (fig 8)^{17,18}




Figure 8:

2. Dissolution Study

Gohel et al proposed a more relevant in vitro dissolution method to evaluate floating drug delivery systems.¹ The in vitro release study for all the formulations were carried out by USP Dissolution Test Apparatus Type-II. The temperature of the dissolution medium (0.1 M HCl, 900 ml) was maintained at 37°C with a stirring rate of 50 rpm, then 5 ml of dissolution medium was taken out at intervals of 1, 2, 3 & 4 hours. Exactly 5 ml of fresh buffer was added to the dissolution vessel after each withdrawal, to maintain a constant volume. Then the withdrawal samples were analyzed by using a U.V.^{19, 20, 21} (fig:9)¹




Figure 9: In vitro dissolution method

3. Resultant Weight Test

An in vitro measuring apparatus has been conceived to determine the real floating capabilities of buoyant dosage forms as a function of time. It operates by measuring the force equivalent to the force F required to keep the object totally submerged in the fluid. (fig:10)¹

The following equation by which weight are tested,

$$F = F_{\text{buoy}} - F_{\text{grav}}$$

$$F = d_f G_v - d_s G_v = (d_f - d_s) G_v$$

$$F = (d_f - M/V) G_v^{20}$$




Figure 10: Effect of various forces on floating

B. In Vivo Method

1. X-Ray Method

X-Ray is a very popular evaluation parameter for floating dosage form now a day. It helps to locate dosage form in the G.I.T and by which one can predict and correlate the gastric emptying time and the passage of dosage form in the GIT.^{1,4,23}

2. Gastroscopy

It comprises of peroral endoscopy, used with a fiberoptic and video system. It is suggested that gastroscopy may be used to inspect visually the effect of prolonged stay in stomach milieu on the FDDS.^{1,23}

3. Ultrasonography

Ultrasonic waves reflected substantially different acoustic impedances across interface enables the imaging of some abdominal organs. Most DFs not have sharp acoustic mismatches result across their interface with the physiological milieu. Therefore, This is not routinely used for the evaluation of Floating Type Drug Delivery System.^{1,23}

REFERENCES

- Rathod H, Patel V, Modasia M .Floing Drug Delivery Sytem:Innovative Approach Of Gastroretention. Int.Re.J.Pharma2010; 1 (3):183-191
- Sarawade A, Ratnaparkhi MP , Chaudhari S .Floating Drug Delivery System: An Overview.Int. J. Res. Dev. Pharm. L. Sci. 2014; 3(5):1106-1115.
- Prasanth VV, Lohumi A, Tribedi S, Mathappan R, Mathew ST . Formulation and Evaluation Of Gastro Retentive Floating Tablet Of Stavudine. Res.Revie. pharm. P'ceutical .scie 2013; 2(3):69-78.
- Chadel A, Chauhan K, Parashar B, Kumar H, Arora S . Floating Drug Delivery System : A Better Approach. Int. Current.P'ceutical.J 2012; 1(5):110-118
- Narang N. An Updated Review On: Floating Drug Delivery System Int J App Pharm, V, 2011; 2(1):1-7.
- Tripathi P, Ubaidulla U, Khar RK, Vishwavibhuti: Floating Drug Delivery System, Int. J. Res. Dev. Pharm. L. Sci. 2012; 6(1):1-10.
- Hafeez A, Maurya A, Singh J, Mittal A, Rana L. An overview on floating microsphere: Gastro Retention Floating drug delivery system. J. Phytopharmacology 2013; 2(3):1-12.
- Mahale GS, Darle ND. Floating Drug Delivery System: A Novel Approach.J.P'ceutical.Scie.Innovation 2012; 1(4):1-6.
- Prajapati ST, Patel LD, Patel CN . Polymer For Floating Drug Delivery System. J.Systematic Reveiw In Pharma. 2010; 2(1):1-7.
- Kaur B, Sharma S, Sharma G, Saini R, Singh S, Nagpal M, Jain UK, Sharma M. A Reveiw Of Floating Drug Delivery System. Asian. J Biomedical .P'ceutical Sci, 2013; 03 (24):1-6.
- Kadwal M, Gnanarajan.G,Kothiyal P. Floating Drug Delivery System: A Novel Approach. The Pharma Innovation. J. 2014; 3(3):57-69.
- Jassal M, Nautiyal U,Kundlas J,Singh D . A Reveiw: Gastroretentive Drug Delivery System. Idian J. Pharm. Bio. Res 2015; 3(1):82-92.
- Yeole PG, Shagufta Khan, V.F.Patel. Floating Drug Delivery System. Indian J. P'ceutical. Sci. 2005; 67(3):265-272.
- Patel J, Amrutiya J, Bhatt P, Javia A, Jain M, Misra A. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. Journal of Microencapsulation. 2018; 35(2):204-17.
- Setia M, Kumar K, Teotia Gastro Retentive Floating Beads: A New Trend of Drug Delivery System, J. Drug Delivery & Therapeutics, 2018; 8(3):169-180.
- Goud MSC Pandey VP: Review Article On Gastroretentive Drug Delivery System. Int J Pharm Biol Sci.2016; 6(3):158-165
- Bharkatiya M, Kitawat S, Ojha A. Floating Drug Delivery System: A Review. J.Drug.Delivery.T'ceutics2014; 4(2):130-134.
- Singh CK, Pandey S, Mishra AC. Floating Drug Delivery System: A Novel Approach. World.J.Pharm.P'ceutical Scie 2019; 8(1): 629-650.
- Kamini, Kaur M, Pooni N, Singh M, Verma K, Dhiman N, Sharma N, Bhandari N. Floating Drug Delivery System: A Reveiw. W.J.Pharm.P'ceutical .Scie2017;6(4):578-594.
- Sutar FY, Prof. Gangurde AB, Prof. Patil DM. A Scientific Review On: Floating Drug Delivery System. Int.J.P'ceutical Res.Scie2014;3(3): 297-334.
- Tandel H, Bhatt P, Jain K, Shahiwala A, Misra A. In-Vitro and In-Vivo Tools in Emerging Drug Delivery Scenario: Challenges and Updates. In: Misra ASA, editor. In-vitro and in-vivo tools in drug delivery research for optimum clinical outcomes. Boca Raton: CRC Press; 2018.
- Choure S, Patil M, Hake G,Mail A, Jadhav S Formulation and Evaluation Of Floating Tablet Of Nizatidine. Int.J. Res. Ayurveda Pharm. 2015;9(4):290-299.
- Patil SH, Talele GS.Formulation development and in vitro and in vivo evaluation of Gastroretentive floating drug delivery system of Lafutidine . Asi.J. P'ceutics 2013; 68-74.